AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23402718 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning (CC) in context A (AAA-COUNTER-group)
Number of subjects: 0
Study 23402718 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning (CC) in context B (ABA-COUNTER-group)
Number of subjects: 0
Study 23402718 — intervention group
Group type: COMPARATOR
Intervention: Extinction in context B (ABA-EXT-group)
Number of subjects: 0
Study 23402718 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning (CC)
Number of subjects: 0
Study 22137072 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (weight of 121 kg)
Number of subjects: 67
Study 22137072 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual body weight (ABW)-based dosing (no upper limit)
Number of subjects: 67
Study 22137072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal body weight (IBW)-based dosing
Number of subjects: 67
Study 19387378 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking forward lunges
Number of subjects: 32
Study 19387378 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping forward lunges
Number of subjects: 32
Study 19387378 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 17511791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 15384960 — intervention group
Group type: EXPERIMENTAL
Intervention: TOSCA telescreening procedures for diabetic retinopathy
Number of subjects: 390
Study 11352416 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (Desmopressin Acetate) administered preoperatively
Number of subjects: 200
Study 11352416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 200
Study 10995074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic extract (Créon 12,000)
Number of subjects: 52
Study 10995074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8044610 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-fluorouracil, Adriamycin, and mitomycin)
Number of subjects: 43
Study 8044610 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (Control)
Number of subjects: 43
Study 31291447 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diets (conventional canola and high-oleic canola)
Number of subjects: 115
Study 31291447 — intervention group
Group type: COMPARATOR
Intervention: Low-MUFA/high-SFA oil blend
Number of subjects: 115
Study 29276865 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFO)
Number of subjects: 200
Study 29276865 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 200
Study 25012156 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 9326
Study 25012156 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 9326
Study 24715012 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and education provision group
Number of subjects: 240
Study 24715012 — intervention group
Group type: COMPARATOR
Intervention: Education provision only group
Number of subjects: 240
Study 21133981 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 50
Study 21133981 — intervention group
Group type: COMPARATOR
Intervention: Control (postponed periodontal treatment)
Number of subjects: 50
Study 19169654 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated and tailored work rehabilitation (CTWR)
Number of subjects: 0
Study 19169654 — intervention group
Group type: COMPARATOR
Intervention: Conventional case management (CCM)
Number of subjects: 0
Study 19169654 — intervention group
Group type: EXPERIMENTAL
Intervention: CTWR
Number of subjects: 0
Study 17078443 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum-blossom needle tapping plus modified yangxue dingfeng tang
Number of subjects: 141
Study 17078443 — intervention group
Group type: COMPARATOR
Intervention: Modified yangxue dingfeng tang
Number of subjects: 141
Study 17078443 — intervention group
Group type: COMPARATOR
Intervention: Oral Benadryl and Vitamin C plus local external application of 10% urea ointment
Number of subjects: 141
Study 15217172 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily dosing (ODD) of gentamicin 5 mg/kg
Number of subjects: 0
Study 15217172 — intervention group
Group type: COMPARATOR
Intervention: Twice daily dosing (TDD) of gentamicin 2.5 mg/kg
Number of subjects: 0
Study 11089713 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (41%)
Number of subjects: 23748
Study 11089713 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (24%)
Number of subjects: 23748
Study 11089713 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics (17%)
Number of subjects: 23748
Study 11089713 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (10%)
Number of subjects: 23748
Study 11089713 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 23748
Study 9291268 — intervention group
Group type: EXPERIMENTAL
Intervention: Clark vestibuloplasty with lyophilized amniotic membrane graft
Number of subjects: 20
Study 9291268 — intervention group
Group type: EXPERIMENTAL
Intervention: Kazanjian vestibuloplasty with lyophilized amniotic membrane graft
Number of subjects: 20
Study 7911400 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15, 30, or 60 mg/day for 4 and 8 weeks
Number of subjects: 292
Study 7911400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 292
Study 7911400 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole
Number of subjects: 292
Study 2431908 — intervention group
Group type: EXPERIMENTAL
Intervention: meglumine diatrizoate at 306 mgI/ml
Number of subjects: 88
Study 2431908 — intervention group
Group type: COMPARATOR
Intervention: iohexol at 240 mgI/ml
Number of subjects: 88
Study 31502026 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilver PTX drug-eluting stent (DES)
Number of subjects: 1240
Study 31502026 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) or bare metal stent (BMS)
Number of subjects: 1240
Study 31502026 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 1240
Study 29708818 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of LI73014F2
Number of subjects: 105
Study 29708818 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of LI73014F2
Number of subjects: 105
Study 29708818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 27043774 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (enalapril + aliskiren)
Number of subjects: 7006
Study 27043774 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 7006
Study 27043774 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren
Number of subjects: 7006
Study 24924842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse ultrasound treatment for popliteal cyamella three times weekly for 8 weeks
Number of subjects: 120
Study 24924842 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly shock wave therapy for popliteal cyamella for the first 6 weeks
Number of subjects: 120
Study 24924842 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic muscular strengthening exercises three times weekly for 8 weeks
Number of subjects: 120
Study 24924842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study 23252526 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (4 mg per kilogram, single subcutaneous dose)
Number of subjects: 100
Study 23252526 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (continued treatment)
Number of subjects: 100
Study 23252526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 21055198 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 235
Study 21055198 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 235
Study 18516715 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated means regression models for recurrent event data
Number of subjects: 0
Study 18516715 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical and numerical procedures for model checking
Number of subjects: 0
Study 15777974 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 60
Study 15777974 — intervention group
Group type: COMPARATOR
Intervention: MS
Number of subjects: 60
Study 12464461 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P infusion
Number of subjects: 12
Study 12464461 — intervention group
Group type: COMPARATOR
Intervention: NaCl infusion (Control)
Number of subjects: 12
Study 10027502 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide and albuterol
Number of subjects: 1041
Study 10027502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil and albuterol
Number of subjects: 1041
Study 10027502 — intervention group
Group type: COMPARATOR
Intervention: Placebo and albuterol
Number of subjects: 1041
Study 10027502 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1041
Study 7560661 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol solution
Number of subjects: 24
Study 7560661 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol solution
Number of subjects: 24
Study 7560661 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol suspension
Number of subjects: 24
Study 7560661 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (400 micrograms)
Number of subjects: 24
Study 7560661 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol suspension
Number of subjects: 24
Study 7560661 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 24
Study 1981218 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 7000
Study 1981218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACE inhibitors)
Number of subjects: 7000
Study 7000628 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate tablets
Number of subjects: 28
Study 7000628 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 28
Study 31479770 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuros dose-to-medium (Dm,m)
Number of subjects: 21
Study 31479770 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuros dose-to-water (Dw,m)
Number of subjects: 21
Study 31479770 — intervention group
Group type: COMPARATOR
Intervention: AAA
Number of subjects: 21
Study 31479770 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuros Dm,m
Number of subjects: 21
Study 31051511 — intervention group
Group type: EXPERIMENTAL
Intervention: aMED diet pattern
Number of subjects: 1367
Study 31051511 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI diet pattern
Number of subjects: 1367
Study 31051511 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet pattern
Number of subjects: 1367
Study 31051511 — intervention group
Group type: EXPERIMENTAL
Intervention: HEI diet pattern
Number of subjects: 1367
Study 31051511 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall metabolomic analysis
Number of subjects: 1367
Study 31051511 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 1367
Study 27921252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg controlled-release tablets
Number of subjects: 180
Study 27921252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone-Naloxone 10/5 mg controlled-release tablets
Number of subjects: 180
Study 27921252 — intervention group
Group type: COMPARATOR
Intervention: Control group (Oxycodone)
Number of subjects: 180
Study 27921252 — intervention group
Group type: COMPARATOR
Intervention: Control group (Oxycodone-Naloxone)
Number of subjects: 180
Study 26851407 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of conditional cash transfers (CCTs)
Number of subjects: 6649
Study 26851407 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6649
Study 24873806 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted vasopressin injection
Number of subjects: 20
Study 24873806 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 20
Study 24873806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 22825784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipocryolysis treatment
Number of subjects: 16
Study 19683269 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-core biopsy protocol (group 1)
Number of subjects: 269
Study 19683269 — intervention group
Group type: COMPARATOR
Intervention: 12-core biopsy protocol (group 2)
Number of subjects: 269
Study 19683269 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat biopsy
Number of subjects: 269
Study 18154961 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Sensor (HFS)
Number of subjects: 12
Study 18154961 — intervention group
Group type: COMPARATOR
Intervention: Swan-Ganz catheter (SG)
Number of subjects: 12
Study 18154961 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography (ECHO)
Number of subjects: 12
Study 15536093 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncope unit evaluation
Number of subjects: 103
Study 15536093 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 103
Study 11302037 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-based anesthesia simulator with debriefing
Number of subjects: 31
Study 11302037 — intervention group
Group type: COMPARATOR
Intervention: Traditional handout study
Number of subjects: 31
Study 9403278 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER, 10 mg once daily
Number of subjects: 30
Study 9403278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR, 20 mg twice daily
Number of subjects: 30
Study 9403278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8427864 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.25‐0.5 units/kg per week s.c. given each evening) for 6 months
Number of subjects: 9
Study 3315286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose metoclopramide and chlorpromazine
Number of subjects: 19
Study 3315286 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide
Number of subjects: 19
Study 31845733 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention (MG)
Number of subjects: 81
Study 31845733 — intervention group
Group type: COMPARATOR
Intervention: Walking intervention (WG)
Number of subjects: 81
Study 29510711 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine anti-relapse treatment
Number of subjects: 0
Study 29510711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27347563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin calcium, 20 mg/d
Number of subjects: 17802
Study 27347563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study 24486033 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive lateral sinus elevation (study group)
Number of subjects: 26
Study 24486033 — intervention group
Group type: COMPARATOR
Intervention: Conventional one-stage lateral sinus elevation (control group)
Number of subjects: 26
Study 22978103 — intervention group
Group type: EXPERIMENTAL
Intervention: Di'ao Xinxuekang Soft Capsule (DK)
Number of subjects: 100
Study 22978103 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 100
Study 20305128 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet combined with a behavioral weight management program including exercise and caloric restriction
Number of subjects: 124
Study 20305128 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet alone
Number of subjects: 124
Study 20305128 — intervention group
Group type: COMPARATOR
Intervention: Usual diet control
Number of subjects: 124
Study 17560883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 303
Study 17560883 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or antiarrhythmic agents)
Number of subjects: 303
Study 15616068 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (doses: 0, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4 mg/kg)
Number of subjects: 220
Study 15616068 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (doses > or = 1.0 mg/kg)
Number of subjects: 220
Study 15616068 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (doses not specified)
Number of subjects: 220
Study 15616068 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP index
Number of subjects: 220
Study 12161228 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1a (IDC with recent-onset pulmonary congestion)
Number of subjects: 65
Study 12161228 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1b (IDC without pulmonary congestion)
Number of subjects: 65
Study 12161228 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (subjects without heart disease)
Number of subjects: 65
Study 10357342 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.20%
Number of subjects: 68
Study 10357342 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.15%
Number of subjects: 68
Study 10357342 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.10%
Number of subjects: 68
Study 7536681 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte‐macrophage‐CSF (rhGM‐CSF)
Number of subjects: 32
Study 7536681 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte‐CSF (rhG‐CSF)
Number of subjects: 32
Study 7536681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CSF therapy)
Number of subjects: 32
Study 2201162 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terlipressin gel
Number of subjects: 44
Study 2201162 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 44
Study 7030227 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dye
Number of subjects: 0
Study 7030227 — intervention group
Group type: COMPARATOR
Intervention: 1% neomycin
Number of subjects: 0
Study 7030227 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulphadiazine ointment
Number of subjects: 0
Study 7030227 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subgallate (astringent powder)
Number of subjects: 0
Study 30852564 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide
Number of subjects: 85
Study 28183565 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (HES) preload
Number of subjects: 30
Study 28183565 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with phenylephrine infusion
Number of subjects: 30
Study 25918346 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI 2 (n = 589)
Number of subjects: 1519
Study 25918346 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI 3 to 4 (n = 599)
Number of subjects: 1519
Study 25918346 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI 5 to 6 (n = 229)
Number of subjects: 1519
Study 25918346 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI ≥ 7 (n = 102)
Number of subjects: 1519
Study 24077886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autologous blood re‐transfusion (ABT) filter system combined with a postoperative ABT filter unit
Number of subjects: 118
Study 24077886 — intervention group
Group type: COMPARATOR
Intervention: High‐vacuum closed‐suction drainage
Number of subjects: 118
Study 22472037 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 g pistachios (RSG)
Number of subjects: 90
Study 22472037 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g pistachios (HSG)
Number of subjects: 90
Study 22472037 — intervention group
Group type: COMPARATOR
Intervention: No pistachios (DCG)
Number of subjects: 90
Study 19118702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold steel endonasal endoscopic dacryocystorhinostomy (EES‐DCR) with circular bicanalicular intubation with silicone tubes (CBIST) guided by a soft probe
Number of subjects: 72
Study 19118702 — intervention group
Group type: COMPARATOR
Intervention: External dacryocystorhinostomy (E‐DCR)
Number of subjects: 72
Study 17374698 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 56
Study 17374698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15446669 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly model
Number of subjects: 723
Study 15446669 — intervention group
Group type: EXPERIMENTAL
Intervention: Family model
Number of subjects: 723
Study 11391123 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide (150 mg twice daily, increasing to 400 mg twice daily)
Number of subjects: 33
Study 11391123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11391123 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide
Number of subjects: 33
Study 9721393 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorous acid preoperative skin antiseptic
Number of subjects: 85
Study 9721393 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate scrub solution
Number of subjects: 85
Study 11271297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 121
Study 11271297 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 121
Study 11271297 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) and FK 506
Number of subjects: 121
Study 3884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (high-dose glycosaminoglycan)
Number of subjects: 30
Study 3884410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30252869 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% green forage
Number of subjects: 116
Study 30252869 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% green forage
Number of subjects: 116
Study 30252869 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% green forage
Number of subjects: 116